Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Treasury Shares: 2009-2024

Historic Treasury Shares for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Dec 2016 value amounting to $2.9 million.

  • Lineage Cell Therapeutics' Treasury Shares fell 83.97% to $2.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was $2.9 million, marking a year-over-year decrease of 83.97%. This contributed to the annual value of $2.9 million for FY2016, which is 83.97% down from last year.
  • Lineage Cell Therapeutics' Treasury Shares amounted to $2.9 million in FY2016, which was down 83.97% from $18.0 million recorded in FY2015.
  • Lineage Cell Therapeutics' 5-year Treasury Shares high stood at $939,000 for FY2022, and its period low was $501,000 during FY2024.
  • Over the past 3 years, Lineage Cell Therapeutics' median Treasury Shares value was $668,000 (recorded in 2023), while the average stood at $702,667.
  • In the last 5 years, Lineage Cell Therapeutics' Treasury Shares soared by 413.81% in 2013 and then tumbled by 83.97% in 2016.
  • Lineage Cell Therapeutics' Treasury Shares (Yearly) stood at $8.4 million in 2012, then soared by 413.81% to $43.0 million in 2013, then slumped by 53.78% to $19.9 million in 2014, then fell by 9.34% to $18.0 million in 2015, then plummeted by 83.97% to $2.9 million in 2016.